HALLE (SAALE), Germany, 18 December 2018 - Probiodrug AG (`Probiodrug`, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer`s disease, announces that the company is scheduled to attend J.P. Morgan Healthcare Conference in San Francisco, Ca, USA. J.P. Morgan Healthcare Conference January 7 -10, 2019, Westin St. Francis Hotel, San Francisco, CA - USA Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to attend and host meetings. The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies,...
|
